Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 110-744, Seoul, Republic of Korea.
BMC Infect Dis. 2013 Jul 19;13:332. doi: 10.1186/1471-2334-13-332.
This study was performed to detect risk factors for Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis.
A retrospective case-control study was designed to identify risk factors for P. aeruginosa bacteremia in cirrhotic patients. The cases were cirrhotic patients with P. aeruginosa bacteremia and the controls were cirrhotic patients with Enterobacteriaceae bacteremia.
Sixty-one cases and the same number of controls were enrolled. In a multivariate analysis, younger age {adjusted odds ratio (aOR) per one year: 0.96, 95% confidence interval: 0.93 - 0.99}, nosocomial acquisition (aOR 3.87, 95% confidence interval: 1.50 - 9.94), preexisting biliary disease (aOR 4.79, 95% confidence interval: 1.92 - 10.47), and recent exposure to immunosuppressive agent (aOR 3.10, 95% confidence interval: 1.23 - 7.82) were associated with P. aeruginosa bacteremia. In the case group the frequency of appropriate initial antibiotic regimens was considerably lower than in the control group: 29.5% vs. 65.6% (P <0.01). However, thirty day mortality did not differ significantly between cases and controls (19.7% vs. 24.6%).
Nosocomial acquisition, preexisting biliary disease, and recent use of immunosuppressive agents are strong predictive factors for P. aeruginosa bacteremia in cirrhotic patients.
本研究旨在探讨肝硬化患者铜绿假单胞菌血症的危险因素。
设计了一项回顾性病例对照研究,以确定肝硬化患者铜绿假单胞菌血症的危险因素。病例为肝硬化合并铜绿假单胞菌血症患者,对照组为肝硬化合并肠杆菌科细菌血症患者。
共纳入 61 例病例和相同数量的对照。多变量分析显示,年龄较小(每增加 1 岁,调整优势比[aOR]为 0.96,95%置信区间[CI]为 0.93-0.99)、医院获得性感染(aOR 3.87,95%CI 为 1.50-9.94)、既往胆道疾病(aOR 4.79,95%CI 为 1.92-10.47)和近期使用免疫抑制剂(aOR 3.10,95%CI 为 1.23-7.82)与铜绿假单胞菌血症相关。在病例组中,初始抗生素方案适当的频率明显低于对照组:29.5%比 65.6%(P<0.01)。然而,病例组和对照组的 30 天死亡率无显著差异(19.7%比 24.6%)。
医院获得性感染、既往胆道疾病和近期使用免疫抑制剂是肝硬化患者铜绿假单胞菌血症的强烈预测因素。